[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE489395T1 - Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung - Google Patents

Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung

Info

Publication number
ATE489395T1
ATE489395T1 AT01997063T AT01997063T ATE489395T1 AT E489395 T1 ATE489395 T1 AT E489395T1 AT 01997063 T AT01997063 T AT 01997063T AT 01997063 T AT01997063 T AT 01997063T AT E489395 T1 ATE489395 T1 AT E489395T1
Authority
AT
Austria
Prior art keywords
molecules
compositions
life
fcrn
proteins
Prior art date
Application number
AT01997063T
Other languages
English (en)
Inventor
Acqua William Dall
Leslie Johnson
Elizabeth Ward
Original Assignee
Medimmune Llc
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc, Univ Texas filed Critical Medimmune Llc
Application granted granted Critical
Publication of ATE489395T1 publication Critical patent/ATE489395T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01997063T 2000-12-12 2001-12-12 Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung ATE489395T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25488400P 2000-12-12 2000-12-12
US28976001P 2001-05-09 2001-05-09
PCT/US2001/048432 WO2002060919A2 (en) 2000-12-12 2001-12-12 Molecules with extended half-lives, compositions and uses thereof

Publications (1)

Publication Number Publication Date
ATE489395T1 true ATE489395T1 (de) 2010-12-15

Family

ID=26944296

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01997063T ATE489395T1 (de) 2000-12-12 2001-12-12 Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung

Country Status (12)

Country Link
US (8) US7083784B2 (de)
EP (5) EP2354149B1 (de)
JP (7) JP4336498B2 (de)
AT (1) ATE489395T1 (de)
AU (1) AU2002248184C1 (de)
CA (1) CA2431600C (de)
CY (1) CY1111283T1 (de)
DE (1) DE60143544D1 (de)
DK (1) DK1355919T3 (de)
ES (2) ES2727425T3 (de)
PT (1) PT1355919E (de)
WO (1) WO2002060919A2 (de)

Families Citing this family (815)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
EP2366713A3 (de) * 1999-01-15 2012-06-27 Genentech, Inc. Polypeptidvarianten mit veränderter Effektorfunktion
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ATE474854T1 (de) * 2000-01-27 2010-08-15 Medimmune Llc Rsv neutralisierende antikörper mit sehr hohen affinität
EP2341074A1 (de) 2000-03-01 2011-07-06 MedImmune, LLC Anti-rsv-f-protein-antikörper
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
US7658921B2 (en) * 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20090042291A1 (en) * 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US20080254027A1 (en) * 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
EP1575509B1 (de) * 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistische monoklonale antikörper und deren anwendungsverfahren
WO2003094859A2 (en) 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en) * 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DE60334141D1 (de) * 2002-10-15 2010-10-21 Facet Biotech Corp VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2512974A1 (en) 2003-01-13 2004-07-29 Macrogenics, Inc. Soluble fc.gamma.r fusion proteins and methods of use thereof
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
CN1798767B (zh) * 2003-04-10 2011-02-16 晶面生物技术公司 通过诱变来改变抗体对FcRn的结合亲和力或血清半衰期
ES2391087T3 (es) * 2003-04-11 2012-11-21 Medimmune, Llc Anticuerpos de IL-9 recombinantes y usos de los mismos
EP1617864A4 (de) * 2003-04-11 2006-06-21 Medimmune Inc Epha2 und nicht-neoplastische hyperproliferative zellstörungen
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DK1639014T3 (da) * 2003-06-13 2011-01-17 Biogen Idec Inc Aglycosyl-anti-CD154 (CD40-ligand)-antistoffer og anvendelser deraf
JP4178514B2 (ja) * 2003-06-27 2008-11-12 東洋紡績株式会社 抗体のスクリーニング方法
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
EP1664116A4 (de) * 2003-08-22 2009-06-03 Biogen Idec Inc Verbesserte antikörper mit veränderter effektor-funktion und herstellungsverfahren dafür
PL2520654T3 (pl) * 2003-08-26 2017-08-31 The Regents Of The University Of Colorado, A Body Corporate Inhibitory aktywności proteazy serynowej i ich zastosowanie w sposobach i kompozycjach do leczenia zakażeń bakteryjnych
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
CA2545539A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
WO2005063815A2 (en) * 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
EP2385069A3 (de) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonataler Fc-Rezeptor (FcRn)-bindende Polypeptidvarianten, dimere Fc-Bindungsproteine und damit in Zusammenhang stehende Verfahren
US20050249723A1 (en) * 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
CA2561264A1 (en) * 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
EP1755673B1 (de) 2004-04-12 2014-07-23 MedImmune, LLC Anti-il-9-antikörperformulierungen und deren verwendung
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
EP1791563A4 (de) * 2004-07-26 2009-07-08 Biogen Idec Inc Anti-cd154-antikörper
BR122018016031B8 (pt) 2004-08-04 2021-07-27 Applied Molecular Evolution Inc processo para produzir um anticorpo monoclonal variante com resposta de adcc realçada
US20060040325A1 (en) * 2004-08-16 2006-02-23 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytoxicity activity
RU2367667C2 (ru) * 2004-08-19 2009-09-20 Дженентек, Инк. Полипептидные варианты с измененной эффекторной функцией
WO2006031994A2 (en) * 2004-09-14 2006-03-23 Xencor, Inc. Monomeric immunoglobulin fc domains
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
AU2005302453A1 (en) * 2004-10-29 2006-05-11 Medimmune, Llc Methods of preventing and treating RSV infections and related conditions
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006053301A2 (en) 2004-11-12 2006-05-18 Xencor, Inc. Fc variants with altered binding to fcrn
EP1752471B9 (de) 2005-01-05 2009-04-15 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Synthetische Immunoglobulindomänen mit in Regionen des Moleküls, die sich von den die Komplementarität bestimmenden Bereichen unterscheiden, modifizierten Bindeeigenschaften
AU2006204791A1 (en) * 2005-01-12 2006-07-20 Xencor, Inc Antibodies and Fc fusion proteins with altered immunogenicity
AU2006206187B2 (en) * 2005-01-24 2011-03-10 Board Of Regents, The University Of Texas System Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
HUE025945T2 (en) 2005-02-15 2016-07-28 Univ Duke Anti-CD19 antibodies and their applications in oncology
US8999943B2 (en) 2005-03-14 2015-04-07 Board Of Regents, The University Of Texas System Antigene oligomers inhibit transcription
EP3050963B1 (de) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Verfahren zur herstellung von polypeptiden durch regulierung der anordnung
EP1868650B1 (de) 2005-04-15 2018-10-03 MacroGenics, Inc. Kovalente diabodies und ihre verwendung
WO2012018687A1 (en) 2010-08-02 2012-02-09 Macrogenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
EP1874816A4 (de) 2005-04-26 2010-08-25 Medimmune Inc Modulation der antikörpereffektorfunktion mittels manipulation von verbindungsregionen
EP1885755A4 (de) 2005-05-05 2009-07-29 Univ Duke Cd19-antikörper-therapie für autoimmunerkrankungen
CN102321174B (zh) 2005-05-06 2013-10-16 津莫吉尼蒂克斯公司 Il-31单克隆抗体及使用方法
US8163881B2 (en) 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
US8309690B2 (en) * 2005-07-01 2012-11-13 Medimmune, Llc Integrated approach for generating multidomain protein therapeutics
CA2652434A1 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized proteins that target ep-cam
DK1919503T3 (en) 2005-08-10 2014-12-15 Macrogenics Inc Identification and preparation of antibodies with variant fc regions and methods of use thereof
CA2624189A1 (en) * 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
CA2625998C (en) 2005-10-06 2015-12-01 Xencor, Inc. Optimized anti-cd30 antibodies
EP1943332A4 (de) 2005-10-14 2011-04-13 Medimmune Inc Zellpräsentation von antikörperbibliotheken
EP2465870A1 (de) 2005-11-07 2012-06-20 Genentech, Inc. Bindepolypeptide mit verschiedenartigen und übereinstimmenden hypervariablen VH/VL-Sequenzen
EP2431467A3 (de) 2005-11-17 2012-05-02 Board Of Regents, The University Of Texas Modulierung der Genexpression durch Oligomere, die auf chromosomale DNA ausgerichtet sind
EP1973576B1 (de) * 2005-11-28 2019-05-15 Genmab A/S Rekombinante monovalente antikörper und herstellungsverfahren dafür
PT1963369E (pt) 2005-11-28 2013-05-28 Zymogenetics Inc Antagonistas de il-21
CA2631327C (en) 2005-12-02 2015-10-13 Genentech, Inc. Her2 binding polypeptides and uses thereof
AU2007212147A1 (en) * 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
WO2007103469A2 (en) 2006-03-06 2007-09-13 Aeres Biomedical Ltd. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
IN2014DN10515A (de) * 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
KR101454508B1 (ko) 2006-05-30 2014-11-04 제넨테크, 인크. 항체 및 면역접합체 및 이들의 용도
US8785599B2 (en) 2006-06-26 2014-07-22 Macrogenics, Inc. FcγRIIB—specific antibodies and methods of use thereof
EP2032159B1 (de) 2006-06-26 2015-01-07 MacroGenics, Inc. Kombination aus fcgammariib-antikörpern und cd20-spezifischen antikörpern sowie verwendungsverfahren dafür
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
WO2008112004A2 (en) 2006-08-03 2008-09-18 Astrazeneca Ab ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
LT2511301T (lt) 2006-08-04 2018-04-10 Medimmune Limited Žmogaus antikūnas prieš erbb2
RS53263B (en) 2006-08-14 2014-08-29 Xencor Inc. CD19 OPTIMIZED ANTIBODY
EP2759549B1 (de) 2006-09-01 2015-08-19 ZymoGenetics, Inc. IL-31-monoklonale Antikörper und Verfahren zu deren Verwendung
JP5401314B2 (ja) 2006-09-08 2014-01-29 メディミューン，エルエルシー ヒト化抗ｃｄ１９抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用
US8394374B2 (en) 2006-09-18 2013-03-12 Xencor, Inc. Optimized antibodies that target HM1.24
US20100143254A1 (en) * 2006-10-16 2010-06-10 Medimmune, Llc Molecules with reduced half-lives, compositions and uses thereof
RS53942B1 (en) 2006-10-27 2015-08-31 Genentech Inc. Antibodies and Immunoconjugates and Their Use
EP2687232A1 (de) 2006-12-06 2014-01-22 MedImmune, LLC Verfahren zur Behandlung von systemischem Lupus erythematodes
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
EP2101807B1 (de) 2006-12-19 2016-05-25 Genentech, Inc. Vegf-spezifische antagonisten für adjuvante und neoadjuvante therapie sowie zur tumorbehandlung im frühstadium
NZ579478A (en) 2007-03-08 2012-08-31 Kalobios Pharmaceuticals Inc Epha3 antibodies for the treatment of solid tumors
EP1980269A1 (de) * 2007-04-13 2008-10-15 Katholieke Universiteit Leuven Prävention von Staphylokokken-Biofilmbildung
BRPI0811466A2 (pt) 2007-05-07 2014-10-14 Medimmune Llc Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
WO2008150494A1 (en) 2007-05-30 2008-12-11 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
US7580304B2 (en) * 2007-06-15 2009-08-25 United Memories, Inc. Multiple bus charge sharing
WO2009000006A1 (en) 2007-06-26 2008-12-31 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Display of binding agents
WO2009006520A1 (en) * 2007-07-03 2009-01-08 Medimmune, Llc Hinge domain engineering
JP2010535032A (ja) 2007-07-31 2010-11-18 メディミューン，エルエルシー 多重特異性エピトープ結合性タンパク質およびその用途
PE20090499A1 (es) 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
EP2190987B1 (de) * 2007-08-21 2012-11-14 MorphoSys AG Verfahren zur Formung von Disulphid-Bindungen
KR101575914B1 (ko) 2007-09-26 2015-12-08 추가이 세이야쿠 가부시키가이샤 Ｃｄｒ의 아미노산 치환에 의해 항체의 등전점을 개변하는 방법
TWI464262B (zh) 2007-09-26 2014-12-11 中外製藥股份有限公司 抗體固定區的變異
KR20100098620A (ko) 2007-11-05 2010-09-08 메디뮨 엘엘씨 경피증의 치료 방법
BRPI0820298A8 (pt) 2007-11-09 2018-05-08 Affitech Res As composições e métodos de anticorpos anti-vegf
RU2504552C2 (ru) 2007-12-07 2014-01-20 Займодженетикс, Инк. Моноклональные антитела против il-21 человека
CA2708251C (en) 2007-12-07 2016-04-12 Zymogenetics, Inc. Humanized antibody molecules specific for il-31
US8795667B2 (en) 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
KR101759457B1 (ko) 2007-12-21 2017-07-31 메디뮨 리미티드 인터루킨-4 수용체 알파(ＩＬ-4Ｒα)에 대한 결합 구성원-173
EP3825329A1 (de) * 2007-12-26 2021-05-26 Xencor, Inc. Fc-varianten mit veränderter bindung zu fcrn
AU2009205995B2 (en) 2008-01-18 2014-04-03 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
EP2080770A1 (de) * 2008-01-21 2009-07-22 MorphoSys AG Proteinöse Bindemoleküle mit Reinigungstags
WO2009100309A2 (en) 2008-02-08 2009-08-13 Medimmune, Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
EP2252631B1 (de) 2008-04-02 2016-04-13 MacroGenics, Inc. Bcr-komplex-spezifische antikörper und verfahren zu ihrer verwendung
ES2587937T3 (es) 2008-04-02 2016-10-27 Macrogenics, Inc. Anticuerpos específicos para HER2/neu y métodos para utilizar los mismos
PT2708559T (pt) 2008-04-11 2018-05-16 Chugai Pharmaceutical Co Ltd Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio
US8314213B2 (en) * 2008-04-18 2012-11-20 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
EP2113255A1 (de) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Zytotoxisches Immunglobulin
AR077718A1 (es) * 2008-07-15 2011-09-21 Genentech Inc Metodos para tratar enfermedades autoinmunes usando anticuerpos anti cd4. formulacion farmaceutica
EP2344536A1 (de) 2008-09-19 2011-07-20 MedImmune, LLC Gegen dll4 gerichtete antikörper und anwendungen davon
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP5913980B2 (ja) * 2008-10-14 2016-05-11 ジェネンテック， インコーポレイテッド 免疫グロブリン変異体及びその用途
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
US20110293605A1 (en) 2008-11-12 2011-12-01 Hasige Sathish Antibody formulation
CA2744158A1 (en) 2008-11-22 2010-05-27 Genentech, Inc. Anti-angiogenesis therapy for the treatment of breast cancer
US8775090B2 (en) * 2008-12-12 2014-07-08 Medimmune, Llc Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
AU2009331528A1 (en) 2008-12-23 2011-08-11 Astrazeneca Ab Targeted binding agents directed to alpha5beta1 and uses thereof
WO2010078526A1 (en) 2008-12-31 2010-07-08 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
EP2391384A4 (de) * 2009-01-29 2012-12-26 Medimmune Llc Humane anti-il-6-antikörper mit verlängerter in-vivo-halbwertszeit und ihre verwendung für behandlungen in der onkologie sowie für autoimmun- und entzündungserkranungen
NZ594950A (en) 2009-03-06 2013-06-28 Kalobios Pharmaceuticals Inc Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
DK2406399T3 (en) 2009-03-09 2018-03-12 Bioatla Llc MIRAC PROTEINS
NZ594668A (en) * 2009-03-16 2012-10-26 Cephalon Australia Pty Ltd Humanised antibodies with anti-tumour activity
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
EP2233500A1 (de) 2009-03-20 2010-09-29 LFB Biotechnologies Optimierte Fc Varianten
AU2010229994B2 (en) 2009-03-25 2016-08-18 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
NZ595792A (en) 2009-04-20 2014-01-31 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17
EP2437767B1 (de) 2009-06-01 2015-07-08 MedImmune, LLC Moleküle mit verlängerter halbwertzeit und verwendungen dafür
EP2711018A1 (de) 2009-06-22 2014-03-26 MedImmune, LLC Manipulierte Fc-Regionen für standortspezifische Konjugation
IN2012DN01328A (de) 2009-08-13 2015-06-05 Crucell Holland Bv
EP3381937A3 (de) 2009-08-13 2018-10-31 The Johns Hopkins University Verfahren zur modulierung der immunfunktion
WO2012006596A2 (en) 2010-07-09 2012-01-12 Calmune Corporation Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
JP6088246B2 (ja) 2009-08-15 2017-03-01 ジェネンテック， インコーポレイテッド 以前に治療された乳癌の治療のための抗血管新生療法
CA2772051C (en) 2009-08-24 2020-08-18 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
IN2012DN03025A (de) 2009-09-09 2015-07-31 Ct Se Llc
US20110189183A1 (en) 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
WO2011037158A1 (ja) 2009-09-24 2011-03-31 中外製薬株式会社 抗体定常領域改変体
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
JP5898082B2 (ja) 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
WO2011047083A1 (en) 2009-10-13 2011-04-21 Oxford Biotherapeutics Ltd. Antibodies against epha10
PT2488554T (pt) 2009-10-14 2019-09-13 Humanigen Inc Anticorpos para epha3
RU2559533C2 (ru) 2009-10-22 2015-08-10 Дженентек, Инк. Антитела против гепсина и способы их применения
DK2496691T3 (en) 2009-11-02 2017-06-06 Univ Washington THERAPEUTIC NUCLEASE COMPOSITIONS AND PROCEDURES
WO2011056997A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
SI2496601T1 (sl) 2009-11-05 2017-09-29 F. Hoffmann-La Roche Ag Tehnike in sestavek za sekrecijo heterolognih polipeptidov
JP5822841B2 (ja) 2009-11-05 2015-11-24 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 変異型のｋｒａｓまたはｂｒａｆ遺伝子を含むがんの治療
US8881354B2 (en) 2009-11-16 2014-11-11 Jtekt Corporation Tool radius adjusting system for boring holder, tool radius adjusting method in machine tool, and machine tool
BR112012012465B1 (pt) 2009-11-24 2023-03-14 Medimmune Limited Anticorpo isolado ou fragmento de ligação do mesmo que se liga especificamente a b7-h1 humano, composição compreendendo o mesmo e usos
EP2516468B1 (de) 2009-12-23 2016-03-02 Synimmune GmbH Anti-flt3-antikörper und verfahren zu deren verwendung
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
AU2011205316B2 (en) 2010-01-13 2015-05-28 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
WO2011089211A1 (en) 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
BR112012020102A2 (pt) 2010-02-10 2016-11-29 Immunogen Inc anticorpos cd20 e usos dos mesmos.
WO2011102845A1 (en) * 2010-02-18 2011-08-25 Transtech Pharma, Inc. Rage fusion protein compositions and methods of use
CN110227154A (zh) 2010-02-23 2019-09-13 霍夫曼-拉罗奇有限公司 用于治疗卵巢癌的抗血管发生疗法
TWI448539B (zh) 2010-02-25 2014-08-11 Asahi Kasei E Materials Corp Copper oxide etching solution and etching method using the same
LT2542256T (lt) 2010-03-04 2019-10-25 Macrogenics Inc Su b7-h3 reaguojantys antikūnai, jų imunologiškai aktyvūs fragmentai ir jų naudojimas
EP2543730B1 (de) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Variante einer konstanten antikörperregion
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CN102822198B (zh) 2010-03-12 2016-08-31 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
NZ629829A (en) 2010-04-30 2015-11-27 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
KR101818274B1 (ko) 2010-05-27 2018-01-12 머크 샤프 앤드 돔 코포레이션 개선된 특성을 갖는 항체의 제조 방법
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
AU2011261362B2 (en) 2010-06-03 2016-06-09 Genentech, Inc. Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
MX2020004438A (es) 2010-06-03 2021-03-25 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
AU2011270959A1 (en) 2010-06-22 2013-01-10 Musc Foundation For Research Development Antibodies to the C3d fragment of complement component 3
NZ605400A (en) 2010-07-09 2015-05-29 Biogen Idec Hemophilia Inc Chimeric clotting factors
WO2012009760A1 (en) 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
AU2011280969A1 (en) 2010-07-23 2013-02-07 Trustees Of Boston University Anti-Despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
BR112013003646B1 (pt) 2010-07-29 2021-09-08 Eleven Biotherapeutics, Inc. Proteína isolada que compreende um domínio de citocina da família de interleucina-1 (il-1) quimérica, seu método de preparação, composição farmacêutica e usos, bem como, ácido nucleico, vetor, e célula hospedeira
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
RU2013113638A (ru) 2010-08-27 2014-10-10 Стем Сентркс, Инк. МОДУЛЯТОРЫ БЕЛКА Notum И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP2611464B1 (de) 2010-09-03 2018-04-25 AbbVie Stemcentrx LLC Neue modulatoren und deren verwendung
EP3219731A1 (de) 2010-10-01 2017-09-20 Oxford BioTherapeutics Ltd Anti-ror1-antikörper
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
RU2600444C2 (ru) 2010-10-13 2016-10-20 Янссен Байотек, Инк. Человеческие антитела к онкостатину м и способы их применения
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
JP6013915B2 (ja) 2010-11-17 2016-10-25 中外製薬株式会社 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子
ME03069B (de) 2010-11-23 2019-01-20 Glaxo Group Ltd Antigenbindende proteine zur bindung von oncostatin m (osm)
CA2818621A1 (en) 2010-11-24 2012-05-31 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf
EP2647706B1 (de) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur wiederholten bindung an mehrere antigenmoleküle
PT2647707T (pt) 2010-11-30 2018-11-15 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de toxicidade
NZ611428A (en) 2010-12-08 2015-07-31 Stemcentrx Inc Novel modulators and methods of use
EA201390923A1 (ru) * 2010-12-22 2013-12-30 Сефалон Острэйлиа Пти Лтд. Модифицированное антитело с улучшенным полупериодом существования
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2012103240A2 (en) 2011-01-25 2012-08-02 Eleven Biotherapeutics, Inc. Receptor binding agents
AU2012212066A1 (en) 2011-02-03 2013-08-15 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
CN107474133B (zh) 2011-02-08 2021-10-15 米迪缪尼有限公司 特异性结合金黄色葡萄球菌α毒素的抗体以及使用方法
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
SG192945A1 (en) 2011-02-25 2013-09-30 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc antibody
JP5926791B2 (ja) 2011-03-29 2016-05-25 ロシュ グリクアート アーゲー 抗体Ｆｃ変種
US20120282176A1 (en) 2011-04-20 2012-11-08 Roche Glycart Ag Method and Constructs for the pH Dependent Passage of the Blood-brain-barrier
CA2833785C (en) 2011-04-21 2022-06-07 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of neuromyelitis optica
SI2704737T1 (en) 2011-04-29 2018-06-29 University Of Washington Therapeutic nucleosomal compositions and procedures
BR112013029892A2 (pt) 2011-05-21 2016-12-20 Macrogenics Inc polipeptídeo, molécula de ligação a antígeno, diacorpo e uso de uma porção polipeptídica de uma proteína de ligação a soro desimunizada
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
JP2014517846A (ja) 2011-05-25 2014-07-24 メルク・シャープ・アンド・ドーム・コーポレーション 改善された特性を有するＦｃ含有ポリペプチドの製造方法
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
SI2718320T1 (en) 2011-06-10 2018-06-29 Medimmune Limited Molecules that bind anti-Pseudomonas psl and their use
AU2012267484B2 (en) 2011-06-10 2017-03-23 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
US9193793B2 (en) 2011-06-13 2015-11-24 Csl Limited Antibodies against G-CSFR and uses thereof
US9938353B2 (en) 2011-06-24 2018-04-10 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
PL2726092T3 (pl) 2011-06-28 2019-11-29 Inhibrx Lp Polipeptydy fuzyjne serpiny i sposoby ich stosowania
PE20140756A1 (es) 2011-06-28 2014-07-04 Oxford Biotherapeutics Ltd Anticuerpos que se unen a bst1
US8986688B2 (en) * 2011-06-28 2015-03-24 Inhibrx, Llc WAP domain fusion polypeptides and methods of use thereof
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
KR20140048276A (ko) 2011-07-15 2014-04-23 온코메드 파마슈티칼스, 인크. Rspo 결합제 및 이의 용도
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
EP2548892A1 (de) 2011-07-22 2013-01-23 CSL Behring GmbH Inhibitorische Antikörper gegen Factor XII/XIIa und ihre Verwendungen
DK2734552T3 (da) 2011-07-22 2024-12-09 Csl Behring Gmbh Indhibitoriske anti-faktor xii/xiia monoklonale antistoffer og deres anvendelser
US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
BR112014001855A2 (pt) 2011-07-27 2017-02-21 Glaxo Group Ltd construto e proteína aglutinantes ao antígeno, dímero, composição farmacêutica, sequência de polinucleotídeo, célula hospedeira e, método para produção do construto
JP2014522868A (ja) 2011-07-29 2014-09-08 イレブン・バイオセラピユーテイクス・インコーポレイテツド 精製タンパク質
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
SI2758073T1 (sl) 2011-09-23 2019-02-28 Oncomed Pharmaceuticals, Inc. Sredstva, ki vežejo VEGF/DLL4, in njihove uporabe
SG10201510341XA (en) 2011-09-30 2016-01-28 Chugai Pharmaceutical Co Ltd Antigen-binding molecule inducing immune response to target antigen
SG11201401101XA (en) 2011-09-30 2014-08-28 Chugai Pharmaceutical Co Ltd Antigen-binding molecule for promoting loss of antigens
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP2762493B1 (de) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur förderung der zersetzung von antigenen mit mehreren biologischen aktivitäten
EP2760889A4 (de) 2011-09-30 2015-04-15 Teva Pharmaceuticals Australia Pty Ltd Antikörper gegen tl1a und ihre verwendung
EP3617313A1 (de) 2011-10-05 2020-03-04 Chugai Seiyaku Kabushiki Kaisha Antigenbindendes molekül zur herstellung eines abstands zwischen einem plasma und einem antigen mit einer saccharidkettenrezeptor-bindenden domäne
JP6140712B2 (ja) 2011-10-11 2017-05-31 メディミューン，エルエルシー ＣＤ４０Ｌ特異的Ｔｎ３由来足場およびその使用方法
MX354988B (es) 2011-10-25 2018-03-28 Prothena Biosciences Ltd Formulaciones de anticuerpo y metodos.
CN109022465B (zh) 2011-10-28 2022-04-29 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
US9220774B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Methods of treating cancer by administering anti-GPR49 antibodies
WO2013067055A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Methods of blocking cancer stem cell growth
AU2012332593B2 (en) 2011-11-01 2016-11-17 Bionomics, Inc. Anti-GPR49 antibodies
JP2014533247A (ja) 2011-11-01 2014-12-11 バイオノミクス インコーポレイテッド 抗体および癌を治療する方法
RU2675319C2 (ru) 2011-11-04 2018-12-18 Займворкс Инк. РАЗРАБОТКА СТАБИЛЬНОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В ДОМЕНЕ Fc
CA2854806A1 (en) 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
US10597439B2 (en) 2011-11-07 2020-03-24 Medimmune Limited Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
EP2780463A4 (de) * 2011-11-18 2015-07-01 Merck Sharp & Dohme Fc enthaltende polypeptide mit erhöhten entzündungshemmenden eigenschaften und erhöhter fcrn-bindung
KR102080535B1 (ko) 2011-11-23 2020-02-24 메디뮨 엘엘씨 Her3에 특이적인 결합 분자 및 이의 용도
SG11201402750SA (en) 2011-11-30 2014-10-30 Chugai Pharmaceutical Co Ltd Drug containing carrier into cell for forming immune complex
EP3712173B1 (de) 2011-12-05 2023-07-12 X-Body, Inc. Pdgf-rezeptor-beta bindende polypeptide
HUE049457T2 (hu) 2011-12-20 2020-09-28 Medimmune Llc Módosított polipeptidek bispecifikus ellenanyag-vázhoz
ES2751386T3 (es) * 2011-12-21 2020-03-31 Amgen Inc Polipéptidos Fc variantes con unión potenciada al receptor de Fc neonatal
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
EP2793944A4 (de) 2011-12-23 2015-09-02 Nicholas B Lydon Immunoglobuline und varianten gegen pathogene mikroben
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
AU2013202648B2 (en) 2012-01-10 2016-05-19 Konkuk University Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
PL2804623T3 (pl) 2012-01-12 2020-03-31 Bioverativ Therapeutics Inc. Chimeryczne polipeptydy czynnika viii i ich zastosowania
EP2623110A1 (de) 2012-01-31 2013-08-07 CSL Behring GmbH Faktor-XII-Hemmer zur Behandlung neurologischer Entzündungserkrankungen
JP6226752B2 (ja) * 2012-02-09 2017-11-08 中外製薬株式会社 抗体のＦｃ領域改変体
PT2814840T (pt) 2012-02-15 2020-01-28 Bioverativ Therapeutics Inc Composições de fator viii e métodos de produção e utilização das mesmas
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
KR102475951B1 (ko) 2012-02-24 2022-12-08 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩＢ를 매개로 항원의 소실을 촉진하는 항원 결합 분자
CN104520324A (zh) 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
LT2831113T (lt) 2012-03-28 2018-06-25 Sanofi Antikūnai prieš bradikinino b1 receptoriaus ligandus
WO2013155346A1 (en) 2012-04-11 2013-10-17 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
US9090694B2 (en) * 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
AU2013256802A1 (en) 2012-04-30 2014-12-11 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
WO2013169657A1 (en) 2012-05-07 2013-11-14 Sanofi Methods for preventing biofilm formation
AU2013258834B2 (en) 2012-05-10 2017-09-07 Zymeworks Bc Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
WO2013180201A1 (ja) 2012-05-30 2013-12-05 中外製薬株式会社 会合化した抗原を消失させる抗原結合分子
KR102677704B1 (ko) 2012-05-30 2024-06-21 추가이 세이야쿠 가부시키가이샤 표적 조직 특이적 항원 결합 분자
JP2015520192A (ja) 2012-06-06 2015-07-16 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｈｉｐｐｏ経路を調節する結合剤およびその使用
EP2858659B1 (de) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Prokoagulationsverbindungen
CA2875247A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
AU2013285355A1 (en) 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
EP3632462A1 (de) 2012-07-06 2020-04-08 Genmab B.V. Dimerprotein mit dreifacher mutation
EP3404105A1 (de) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Einkettige faktor-viii-polypeptide exprimierende zelllinie und verwendungen davon
DK2882450T3 (da) 2012-07-11 2020-02-24 Bioverativ Therapeutics Inc Faktor viii-kompleks med xten og von willebrand-faktorprotein samt anvendelser deraf
SI3495387T1 (sl) 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
WO2014018625A1 (en) 2012-07-25 2014-01-30 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
EP2888279A1 (de) 2012-08-22 2015-07-01 Glaxo Group Limited Anti-lrp6-antikörper
TWI766493B (zh) 2012-08-24 2022-06-01 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
EP3597747B1 (de) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Maus-fgcgammarii-spezifischer fc-antikörper
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
EP2928483A4 (de) 2012-12-04 2016-06-08 Oncomed Pharm Inc Immuntherapie mit bindemitteln
SG11201504764SA (en) 2012-12-19 2015-07-30 Amplimmune Inc Anti-human b7-h4 antibodies and their uses
SG10201709290XA (en) 2012-12-21 2018-01-30 Medimmune Llc Anti-H7cr Antibodies
AU2013372331A1 (en) 2013-01-10 2015-07-23 Genmab B.V. Human IgG1 Fc region variants and uses thereof
CN105051064A (zh) 2013-01-24 2015-11-11 葛兰素史克知识产权开发有限公司 抗TNF-α抗原结合蛋白
ES2715710T3 (es) 2013-01-25 2019-06-05 Shire Human Genetic Therapies Folistatina en el tratamiento de la distrofía muscular de Duchenne
NZ711543A (en) 2013-02-01 2020-08-28 Univ California Anti-cd83 antibodies and use thereof
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
EP4219552A3 (de) 2013-02-07 2023-09-13 CSL Ltd. Il-11r-bindende proteine und verwendungen davon
RS61387B2 (sr) 2013-02-15 2024-06-28 Bioverativ Therapeutics Inc Gen optimizovanog faktora viii
ME03394B (de) 2013-02-22 2020-01-20 Medimmune Ltd Neuartige antikörperkonjugate und verwendungen davon
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US10286047B2 (en) 2013-03-08 2019-05-14 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
EA202091166A1 (ru) 2013-03-11 2021-04-30 Джензим Корпорейшн ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
KR20230020013A (ko) 2013-03-11 2023-02-09 젠자임 코포레이션 당조작을 통한 부위-특이적 항체-약물 접합
AU2014243839B2 (en) 2013-03-13 2019-01-03 Buzzard Pharmaceuticals AB Chimeric cytokine formulations for ocular delivery
US20140271641A1 (en) * 2013-03-14 2014-09-18 University Of Guelph Thrombospondin-1 polypeptides and methods of using same
ES2882183T3 (es) 2013-03-14 2021-12-01 Univ Duke Moléculas biespecíficas que son inmunorreactivas con células efectoras inmunitarias que expresan un receptor activador
ES2699599T3 (es) 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Variantes de Fc
UY35415A (es) 2013-03-15 2014-10-31 Glaxosmithkline Ip Dev Ltd Proteínas de unión a antígeno.
WO2014151910A1 (en) 2013-03-15 2014-09-25 Amgen Inc. Heterodimeric bispecific antibodies
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
CN105451767B (zh) 2013-03-15 2019-10-18 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
CA2904527A1 (en) 2013-03-15 2014-09-18 Abbvie Biotechnology Ltd. Anti-cd25 antibodies and their uses
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
JP6387392B2 (ja) 2013-03-15 2018-09-05 バイオベラティブ セラピューティクス インコーポレイテッド 第ｉｘ因子ポリペプチド製剤
CA2904532A1 (en) 2013-03-15 2014-09-18 Abbvie Biotechnology Ltd. Anti-cd25 antibodies and their uses
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
EP2982689B1 (de) 2013-04-02 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Varianten der fc-region
EP2992013B1 (de) 2013-04-29 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38-antikörper und fusionen davon mit abgeschwächtem interferon-alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
SG11201509566RA (en) 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015021423A2 (en) 2013-08-08 2015-02-12 Biogen Idec Ma Inc. Purification of chimeric fviii molecules
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
MX2016001851A (es) 2013-08-13 2016-05-16 Sanofi Sa Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos.
TW201722994A (zh) 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EP2840091A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
EP2839842A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
EP3892294A1 (de) 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Konjugationsverfahren stellenspezifischer antikörper und zusammensetzungen
CA2922529A1 (en) 2013-08-28 2015-03-05 Stemcentrx, Inc. Novel sez6 modulators and methods of use
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
EP4130044A1 (de) 2013-09-13 2023-02-08 BeiGene Switzerland GmbH Anti-pd1-antikörper sowie verwendung davon in therapeutika und diagnostika
US20160257748A1 (en) 2013-09-25 2016-09-08 Amgen Inc. V-c-fc-v-c antibody
HUE057005T2 (hu) 2013-09-25 2022-04-28 Bioverativ Therapeutics Inc Oszlopon történõ vírusinaktiváló eljárások
KR102441231B1 (ko) 2013-09-27 2022-09-06 추가이 세이야쿠 가부시키가이샤 폴리펩티드 이종 다량체의 제조방법
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
KR20240151882A (ko) 2013-10-02 2024-10-18 메디뮨 엘엘씨 중화 항-인플루엔자 a 항체 및 이의 용도
PE20160561A1 (es) 2013-10-11 2016-06-03 Oxford Biotherapeutics Ltd Anticuerpos conjugados contra ly75 para el tratamiento de cancer
US10988745B2 (en) 2013-10-31 2021-04-27 Resolve Therapeutics, Llc Therapeutic nuclease-albumin fusions and methods
MX2016005763A (es) 2013-11-06 2016-08-19 Stemcentrx Inc Anticuerpos anti-claudina novedosos y metodos de uso.
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
WO2015081073A2 (en) * 2013-11-26 2015-06-04 The Brigham And Women's Hospital, Inc. Compositions and methods for modulating an immune response
CN105829547A (zh) 2013-12-02 2016-08-03 昂科梅德制药有限公司 与Wnt途径抑制剂有关的预测性生物标记物的鉴别
MX2016007312A (es) 2013-12-04 2017-01-13 Chugai Pharmaceutical Co Ltd Moleculas de union al antigeno, cuya actividad de union al antigeno varia de acuerdo con la concentracion de los compuestos y bibliotecas de dichas moleculas.
ES2758508T3 (es) 2013-12-09 2020-05-05 Allakos Inc Anticuerpos dirigidos contra Siglec-8 y métodos de uso de los mismos
EP2883883A1 (de) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
CN112142843B (zh) 2013-12-24 2024-10-18 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
CN117106095A (zh) 2014-01-10 2023-11-24 比奥贝拉蒂治疗公司 因子viii嵌合蛋白及其用途
JP2017506640A (ja) 2014-02-14 2017-03-09 セントローズ， エルエルシー 細胞外標的化薬物共役体
EP4014995A1 (de) 2014-02-28 2022-06-22 Allakos Inc. Verfahren und zusammensetzungen zur behandlung von siglec-8-assoziierten krankheiten
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
US9738702B2 (en) * 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
MX2016011637A (es) 2014-03-14 2017-04-13 Genentech Inc Metodos y composiciones para secrecion de polipeptidos heterologos.
ES2940903T3 (es) 2014-03-19 2023-05-12 Genzyme Corp Glucomanipulación específica del sitio de restos orientadores
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
US10202462B2 (en) 2014-03-21 2019-02-12 X-Body, Inc. Bi-specific antigen-binding polypeptides
NZ724815A (en) 2014-04-04 2017-11-24 Bionomics Inc Humanized antibodies that bind lgr5
SG11201609178SA (en) 2014-04-08 2016-12-29 Medimmune Llc Binding molecules specific for il-21 and uses thereof
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
WO2015175874A2 (en) 2014-05-16 2015-11-19 Medimmune, Llc Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
US10155818B2 (en) 2014-05-28 2018-12-18 Agenus Inc. Anti-GITR antibodies and methods of use thereof
WO2015189249A1 (en) * 2014-06-12 2015-12-17 F. Hoffmann-La Roche Ag Method for selecting antibodies with modified fcrn interaction
JP6655074B2 (ja) 2014-06-20 2020-02-26 ジェネンテック， インコーポレイテッド シャガシンに基づく足場組成物、方法及び使用
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
US10544225B2 (en) 2014-07-03 2020-01-28 Beigene, Ltd. Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
RU2739952C2 (ru) 2014-07-15 2020-12-30 МЕДИММЬЮН, ЭлЭлСи Нейтрализующие антитела к вирусу гриппа b и пути их применения
US10428146B2 (en) 2014-07-22 2019-10-01 Cb Therapeutics, Inc. Anti PD-1 antibodies
SG11201700687TA (en) 2014-08-05 2017-02-27 Cb Therapeutics Inc Anti-pd-l1 antibodies
EP4108256A1 (de) 2014-08-11 2022-12-28 University of Massachusetts Anti-ospa-antikörper und verfahren zur verwendung
EA039598B9 (ru) 2014-09-03 2022-03-10 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23а и фно-альфа, и его применение
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
WO2016046778A2 (en) 2014-09-25 2016-03-31 Amgen Inc Protease-activatable bispecific proteins
MX2017003897A (es) 2014-09-26 2017-06-28 Bayer Pharma AG Derivados estabilizados de adrenomedulina y uso de los mismos.
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CN107108721B (zh) 2014-09-29 2021-09-07 杜克大学 包含hiv-1包膜靶向臂的双特异性分子
KR20230153495A (ko) * 2014-10-01 2023-11-06 메디뮨 리미티드 티카그렐로에 대한 항체 및 이의 사용 방법
US10064952B2 (en) 2014-10-09 2018-09-04 Genzyme Corporation Glycoengineered antibody drug conjugates
WO2016061286A2 (en) 2014-10-14 2016-04-21 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
CA2965170A1 (en) 2014-10-23 2016-04-28 Dendrocyte Biotech Pty Ltd Cd83 binding proteins and uses thereof
UA125637C2 (uk) 2014-10-29 2022-05-11 Тева Фармасьютікалз Острейліа Пті Лтд ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
RU2713131C1 (ru) * 2014-11-06 2020-02-03 Ф. Хоффманн-Ля Рош Аг ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМИ СВОЙСТВАМИ СВЯЗЫВАНИЯ FcRn И БЕЛКА А
MX2017005976A (es) 2014-11-10 2017-06-29 Medimmune Ltd Moleculas de union especificas para grupo de diferenciacion 73 (cd73) y usos de las mismas.
WO2016075176A1 (en) 2014-11-11 2016-05-19 Medimmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
US10508151B2 (en) 2014-11-19 2019-12-17 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
CN107250158B (zh) 2014-11-19 2022-03-25 基因泰克公司 抗转铁蛋白受体/抗bace1多特异性抗体和使用方法
CA2968357A1 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
EP3789399A1 (de) 2014-11-21 2021-03-10 Bristol-Myers Squibb Company Antikörper mit modifizierten schweren konstanten regionen
US9382321B2 (en) 2014-11-26 2016-07-05 Adventis Health System/Sunbelt, Inc. Effector-deficient anti-CD32A antibodies
RU2017120039A (ru) 2014-12-10 2019-01-10 Дженентек, Инк. Антитела к рецепторам гематоэнцефалического барьера и способы их применения
UA128712C2 (uk) 2014-12-19 2024-10-09 Чугаі Сейяку Кабусікі Кайся Антитіла проти c5 та способи застосування
EA201791253A1 (ru) 2014-12-19 2018-04-30 Чугаи Сейяку Кабусики Кайся Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
EP3233120A4 (de) 2014-12-19 2018-05-30 Monash University Il-21-antikörper
EP3237450B1 (de) 2014-12-22 2021-03-03 The Rockefeller University Anti-mertk-antikörper und verwendungen davon
US10189902B2 (en) 2014-12-23 2019-01-29 Bristol-Myers Squibb Company Antibodies to TIGIT
SG10201906471PA (en) 2015-01-14 2019-09-27 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
WO2016123454A1 (en) 2015-01-29 2016-08-04 Board Of Trustees Of Miching State University Cryptic polypeptides and uses thereof
TW202248212A (zh) 2015-02-05 2022-12-16 日商中外製藥股份有限公司 包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
WO2016131893A1 (en) 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
AU2016224409B2 (en) 2015-02-27 2021-01-28 Chugai Seiyaku Kabushiki Kaisha Composition for treating IL-6-related diseases
NZ734416A (en) 2015-03-09 2024-12-20 argenx BV Methods of reducing serum levels of fc-containing agents using fcrn antagonists
BR112017020955A2 (pt) 2015-03-31 2018-07-10 Medimmune Limited forma de il33, formas mutadas de il33, anticorpos, ensaios e métodos de uso dos mesmos
FR3034420A1 (fr) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303
EP3279216A4 (de) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha Verfahren zur herstellung von polypeptid-hetero-oligomer
HUE061253T2 (hu) 2015-05-29 2023-06-28 Bristol Myers Squibb Co Antitestek OX40 ellen és azok felhasználásai
KR102141446B1 (ko) 2015-06-04 2020-08-06 오스페달레 산 라파엘 에스.알.엘. Ｉｇｆｂｐ3 및 이의 용도
CN107921132B (zh) 2015-06-04 2021-05-07 圣拉斐尔医院有限公司 糖尿病和igfbp3/tmem219轴抑制剂
US10112990B2 (en) 2015-06-05 2018-10-30 Genentech, Inc. Anti-Tau antibodies and methods of use
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
WO2016205567A1 (en) 2015-06-17 2016-12-22 Allakos Inc. Methods and compositions for treating fibrotic diseases
WO2017004016A1 (en) 2015-06-29 2017-01-05 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
PE20180774A1 (es) 2015-07-23 2018-05-07 Boehringer Ingelheim Int Compuesto que se dirige a il-23a y al factor de activacion de linfocitos b (baff) y usos de estos
LT3328419T (lt) 2015-07-30 2021-11-10 Macrogenics, Inc. Pd-1 surišančios molekulės ir jų panaudojimo būdai
JP2018529756A (ja) 2015-07-31 2018-10-11 メディミューン リミテッド ヘプシジン媒介性障害を治療するための方法
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
KR20220131277A (ko) 2015-09-01 2022-09-27 아게누스 인코포레이티드 항-pd-1 항체 및 이를 이용하는 방법
SG10201913864RA (en) 2015-09-02 2020-03-30 Immutep Sas Anti-LAG-3 Antibodies
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
US20190022092A1 (en) 2015-09-15 2019-01-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
EP3353204B1 (de) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-spezifischer anti-vegf/dll4-antikörper zur verwendung bei der behandlung von platin-resistentem eierstockkrebs
RU2022102624A (ru) 2015-10-01 2022-03-10 Хит Байолоджикс, Инк. Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков
MA45429A (fr) 2015-10-08 2019-05-01 Macrogenics Inc Polythérapie pour le traitement du cancer
US10676531B2 (en) 2015-10-12 2020-06-09 Aprogen Kic Inc. Anti-CD43 antibody and use thereof for cancer treatment
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
TWI726936B (zh) 2015-11-10 2021-05-11 美商麥迪紐有限責任公司 對asct2具專一性之結合分子及其用途
EP3383909B1 (de) 2015-11-30 2020-06-17 AbbVie Inc. Anti-hulrrc15-antikörper-wirkstoff-konjugate und verfahren zu deren verwendung
AU2016365117A1 (en) 2015-11-30 2018-05-31 Abbvie Biotherapeutics Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
AU2016364889B2 (en) 2015-12-02 2024-01-04 Agenus Inc. Antibodies and methods of use thereof
WO2017106061A1 (en) 2015-12-14 2017-06-22 Macrogenics, Inc. Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US10793643B2 (en) 2015-12-31 2020-10-06 Jiangsu Hengrui Medicine Co., Ltd. PCSK9 antibody, antigen-binding fragment thereof, and medical application thereof
EP3401336A4 (de) 2016-01-05 2020-01-22 Jiangsu Hengrui Medicine Co., Ltd. Pcsk9-antikörper, antigenbindendes fragment davon und medizinische verwendungen davon
KR20180100659A (ko) 2016-01-08 2018-09-11 백시바디 에이에스 치료적 항암 네오에피토프 백신
EP3411478B1 (de) 2016-02-01 2022-06-08 Bioverativ Therapeutics Inc. Optimierte faktor-viii-gene
AR108034A1 (es) 2016-02-17 2018-07-11 Macrogenics Inc Moléculas de unión a ror1, y métodos de uso de las mismas
WO2017151176A1 (en) 2016-03-04 2017-09-08 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
AU2017228475A1 (en) 2016-03-04 2018-09-13 Shire Human Genetic Therapies, Inc. Recombinant follistatin-Fc fusion proteins and use in treating duchenne muscular dystrophy
KR20230038311A (ko) 2016-03-04 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
TW202342540A (zh) 2016-03-14 2023-11-01 日商中外製藥股份有限公司 用於癌之治療的細胞傷害誘導治療劑
US11066464B2 (en) 2016-03-21 2021-07-20 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
CA3018081A1 (en) 2016-03-22 2017-09-28 Bionomics Limited Administration of an anti-lgr5 monoclonal antibody
MA45473A (fr) 2016-04-04 2019-02-13 Shire Human Genetic Therapies Inhibiteur de c1 estérase conjugué et ses utilisations
IL262010B (en) 2016-04-04 2022-09-01 Bioverativ Usa Inc Anti-complement factor bb antibodies and uses thereof
MY198114A (en) 2016-04-15 2023-08-04 Macrogenics Inc Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
WO2017184942A1 (en) 2016-04-21 2017-10-26 Abbvie Stemcentrx Llc Novel anti-bmpr1b antibodies and methods of use
CA3024508A1 (en) 2016-05-27 2017-11-30 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
FI3468997T3 (fi) 2016-06-08 2023-10-31 Xencor Inc Igg4:ään liittyvien sairauksien hoito anti-cd19-vasta-aineilla, jotka ristisitoutuvat cd32b:een
KR102456739B1 (ko) 2016-06-17 2022-10-19 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체 및 사용 방법
LT3478713T (lt) 2016-06-30 2022-06-10 Prothena Biosciences Limited Kompozicijos, skirtos amiloidozės gydymui
EP4410378A3 (de) 2016-07-01 2024-10-09 Resolve Therapeutics, LLC Optimierte binucleasefusionen und verfahren
NZ749997A (en) 2016-07-05 2022-11-25 Beigene Ltd Combination of a pd-l antagonist and a raf inhibitor for treating cancer
AU2017292184A1 (en) 2016-07-08 2019-02-07 Staten Biotechnology B.V. Anti-Apoc3 antibodies and methods of use thereof
EP3484923A1 (de) 2016-07-15 2019-05-22 Takeda Pharmaceutical Company Limited Verfahren und materialien zur beurteilung der reaktion auf plasmablasten- und plasmazellenabreichernde therapien
CN117717604A (zh) 2016-07-19 2024-03-19 梯瓦制药澳大利亚股份有限公司 抗cd47联合治疗
US11858980B2 (en) 2016-08-02 2024-01-02 Visterra, Inc. Engineered polypeptides and uses thereof
US11447542B2 (en) 2016-08-05 2022-09-20 Medimmune, Llc Anti-O2 antibodies and uses thereof
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
US20210332112A1 (en) * 2016-08-15 2021-10-28 Board Of Regents, The University Of Texas System Stabilized pertussis antibodies with extended half-life
US10538579B2 (en) 2016-08-15 2020-01-21 Board Of Regents, The University Of Texas System Bispecific pertussis antibodies
PT3500299T (pt) 2016-08-19 2024-02-21 Beigene Switzerland Gmbh Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
JP2019534858A (ja) 2016-09-09 2019-12-05 ジェネンテック， インコーポレイテッド Ｆｒｉｚｚｌｅｄの選択的ペプチド阻害剤
EP3512883A1 (de) 2016-09-13 2019-07-24 Humanigen, Inc. Epha3-antikörper zur behandlung von lungenfibrose
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP3526256A1 (de) 2016-10-11 2019-08-21 Agenus Inc. Anti-lag-3-antikörper und verfahren zur verwendung davon
KR20190064636A (ko) 2016-10-19 2019-06-10 메디뮨 엘엘씨 항-o1 항체 및 이의 용도
TW202300515A (zh) 2016-10-20 2023-01-01 法商賽諾菲公司 抗ｃｈｉｋｖ抗體及其用途
KR102695416B1 (ko) 2016-10-21 2024-08-13 아디맵 엘엘씨 항-호흡기 세포융합 바이러스 항체, 그리고 이의 생성 방법 및 사용 방법
WO2018075954A2 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
EP3974447A3 (de) 2016-10-21 2022-09-07 Adimab, LLC Antikörper gegen das respiratorische synzytialvirus und verfahren zu deren erzeugung und verwendung
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
MX2019006446A (es) 2016-12-02 2019-12-11 Bioverativ Therapeutics Inc Métodos para inducir tolerancia inmunológica a factores de coagulación.
CA3045660A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
BR112019011582A2 (pt) 2016-12-07 2019-10-22 Agenus Inc. anticorpos e métodos de utilização dos mesmos
EP3551655A2 (de) 2016-12-07 2019-10-16 Genentech, Inc. Anti-tau-antikörper und verfahren zu deren verwendung
EP4289484A3 (de) 2016-12-07 2024-03-06 Agenus Inc. Anti-ctla-4-antikörper und verfahren zur verwendung davon
PE20201186A1 (es) 2016-12-07 2020-11-03 Genentech Inc Anticuerpos antitau y metodos de uso
IL267113B2 (en) 2016-12-21 2024-09-01 Cephalon Llc Antibodies that bind specifically to human IL-15 and their uses
ES2912266T3 (es) 2016-12-23 2022-05-25 Immunogen Inc Inmunoconjugados dirigidos a ADAM9 y procedimientos de uso de los mismos
CN110167591B (zh) 2016-12-23 2023-09-26 宏观基因有限公司 Adam9结合分子及使用其的方法
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN110462027A (zh) 2017-01-06 2019-11-15 艾欧凡斯生物治疗公司 用肿瘤坏死因子受体超家族（tnfrsf）激动剂扩增肿瘤浸润淋巴细胞（til）及til和tnfrsf激动剂的治疗组合
JP2020503351A (ja) 2017-01-06 2020-01-30 アイオバンス バイオセラピューティクス，インコーポレイテッド カリウムチャネルアゴニストによる腫瘍浸潤リンパ球の増殖及びその治療的使用
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
CN110536695B (zh) 2017-01-25 2024-05-10 分子模板公司 包括去免疫化的志贺毒素a亚基效应子和cd8+ t细胞表位的细胞靶向分子
JP2020505029A (ja) * 2017-01-25 2020-02-20 メディミューン，エルエルシー リラキシン融合ポリペプチドおよびその使用
WO2018144773A1 (en) 2017-02-01 2018-08-09 Yale University Treatment of diuretic resistance
KR102654105B1 (ko) 2017-02-17 2024-04-04 사노피 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
US10626169B2 (en) 2017-02-17 2020-04-21 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
CA3053375A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Engineered transferrin receptor binding polypeptides
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
EP3585410B9 (de) 2017-02-27 2023-10-04 Shattuck Labs, Inc. Chimäre proteine auf vsig8-basis
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
JP7222901B2 (ja) 2017-03-16 2023-02-15 メドイミューン・リミテッド 抗ｐａｒ２抗体及びその使用
UY37651A (es) 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
MX2019012223A (es) 2017-04-13 2019-12-09 Agenus Inc Anticuerpos anti-cd137 y metodos de uso de los mismos.
US20200033347A1 (en) 2017-04-18 2020-01-30 Universite Libre De Bruxelles Biomarkers And Targets For Proliferative Diseases
CN110536694A (zh) 2017-04-20 2019-12-03 Atyr 医药公司 用于治疗肺部炎症的组合物和方法
EP3612560A1 (de) 2017-04-21 2020-02-26 Staten Biotechnology B.V. Anti-apoc3-antikörper und verfahren zur verwendung davon
FI3618863T3 (fi) 2017-05-01 2023-09-01 Agenus Inc Anti-TIGIT-vasta-aineita ja menetelmiä niiden käyttämiseksi
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
BR112019022912A2 (pt) 2017-05-05 2020-05-26 Allakos Inc. Métodos e composições para tratar doenças oculares alérgicas
TW201904578A (zh) 2017-05-10 2019-02-01 美商艾歐凡斯生物治療公司 源自液體腫瘤之腫瘤浸潤性淋巴細胞的擴增和該經擴增腫瘤浸潤性淋巴細胞之治療用途
MX2019013523A (es) 2017-05-12 2020-07-14 Takeda Pharmaceuticals Co Proteínas de fusión de folistatina-fc recombinante y uso en el tratamiento de la distrofia muscular de duchenne.
JOP20190271A1 (ar) * 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
BR112019024419A2 (pt) 2017-05-25 2020-07-14 Bristol-Myers Squibb Company anticorpos compreendendo regiões constantes pesadas modificadas
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
TW201906866A (zh) 2017-06-26 2019-02-16 英屬開曼群島商百濟神州有限公司 酸性鞘磷脂酶缺乏症患者中異常骨狀況的治療
CA3069756A1 (en) 2017-07-27 2019-01-31 Alexion Pharmaceuticals, Inc. High concentration anti-c5 antibody formulations
AU2018313921B2 (en) 2017-08-09 2024-12-19 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
US10947295B2 (en) 2017-08-22 2021-03-16 Sanabio, Llc Heterodimers of soluble interferon receptors and uses thereof
CN111094352B (zh) 2017-08-25 2024-10-01 戊瑞治疗有限公司 B7-h4抗体及其使用方法
CA3096821A1 (en) 2017-09-27 2019-04-04 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
JP7518764B2 (ja) 2017-10-26 2024-07-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
CN111315772A (zh) 2017-10-31 2020-06-19 斯塔顿生物技术有限公司 抗apoc3抗体及其使用方法
JP2021503885A (ja) 2017-11-22 2021-02-15 アイオバンス バイオセラピューティクス，インコーポレイテッド 末梢血からの末梢血リンパ球（ｐｂｌ）の拡大培養
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
ES2939461T3 (es) 2017-11-29 2023-04-24 Csl Ltd Método para tratar o prevenir la lesión por isquemia-reperfusión
EA202091410A1 (ru) 2017-12-08 2021-01-13 Ардженкс Бвба Применение антагонистов fcrn для лечения генерализованной миастении гравис
RU2020122822A (ru) 2017-12-12 2022-01-13 Макродженикс, Инк. Биспецифичные связывающие cd16 молекулы и их применение при лечении заболеваний
US20210369775A1 (en) 2017-12-15 2021-12-02 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
EP3498293A1 (de) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Behandlung monogener erkrankungen mit einem anti-cd45rc-antikörper
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
WO2019133747A1 (en) 2017-12-27 2019-07-04 Bristol-Myers Squibb Company Anti-cd40 antibodies and uses thereof
FR3076294B1 (fr) 2017-12-29 2022-01-28 Lab Francais Du Fractionnement Procede de purification d'anticorps a partir de lait brut
SG11202006157VA (en) 2018-01-05 2020-07-29 Corvidia Therapeutics Inc Methods for treating il-6 mediated inflammation without immunosuppression
CA3087569A1 (en) 2018-01-09 2019-07-18 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
JP2021510737A (ja) 2018-01-12 2021-04-30 武田薬品工業株式会社 抗ｃｄ３８抗体の皮下投与
MX2020008152A (es) 2018-02-01 2020-11-24 Bioverativ Therapeutics Inc Uso de vectores lentivirales que expresan el factor viii.
MA51875A (fr) 2018-02-13 2020-12-23 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
CA3091184A1 (en) 2018-02-14 2019-08-22 Viela Bio, Inc. Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases
NZ767006A (en) 2018-02-15 2024-12-20 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
CN111971308A (zh) 2018-03-02 2020-11-20 戊瑞治疗有限公司 B7-h4抗体及其使用方法
MX2020009296A (es) 2018-03-15 2020-11-13 Chugai Pharmaceutical Co Ltd Anticuerpos anti-virus del dengue que tienen reactividad cruzada con el virus zika y metodos de uso.
WO2019183209A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
AU2019240111A1 (en) * 2018-03-21 2020-09-17 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
AU2019237215B2 (en) 2018-03-23 2023-11-02 Université Libre de Bruxelles Wnt signaling agonist molecules
CA3094112A1 (en) 2018-03-28 2019-10-03 Bristol-Myers Squibb Company Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
AU2019244478A1 (en) 2018-03-28 2020-11-12 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-CD38 antibodies
KR20210021468A (ko) 2018-05-14 2021-02-26 웨어울프 세라퓨틱스, 인크. 활성화가능한 사이토카인 폴리펩타이드 및 이의 사용 방법
DK3794024T5 (da) 2018-05-14 2024-08-19 Werewolf Therapeutics Inc Aktiverbare interleukin-2 polypeptider og fremgangsmåder til anvendelse heraf
WO2019218009A1 (en) 2018-05-16 2019-11-21 Csl Limited Soluble complement receptor type 1 variants and uses thereof
JP2021523878A (ja) 2018-05-18 2021-09-09 バイオベラティブ セラピューティクス インコーポレイテッド 血友病ａを処置する方法
WO2019236417A1 (en) 2018-06-04 2019-12-12 Biogen Ma Inc. Anti-vla-4 antibodies having reduced effector function
MA52790A (fr) 2018-06-08 2021-04-14 Argenx Bvba Compositions et méthodes de traitement de la thrombopénie immune
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
JP7549536B2 (ja) 2018-06-15 2024-09-11 アミル テラピュティクス エスエールエル 全般的アミロイド相互作用モチーフ（ｇａｉｍ）
TWI831797B (zh) 2018-06-26 2024-02-11 美商伊繆諾金公司 靶向adam9之免疫接合物及其使用方法
WO2020010117A2 (en) 2018-07-03 2020-01-09 Bristol-Myers Squibb Company Fgf21 formulations
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
KR20210035832A (ko) 2018-07-19 2021-04-01 리제너론 파아마슈티컬스, 인크. Bcma 특이성을 갖는 키메라 항원 수용체 및 이의 용도
KR20210042128A (ko) 2018-08-09 2021-04-16 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도
CA3109354A1 (en) 2018-08-29 2020-03-05 Shattuck Labs, Inc. Combination therapies comprising pd-1-based chimeric proteins
CN113365663A (zh) * 2018-08-30 2021-09-07 Hcw生物科技公司 单链嵌合多肽和其用途
SG11202101779RA (en) * 2018-08-30 2021-03-30 Hcw Biologics Inc Multi-chain chimeric polypeptides and uses thereof
EP3844182A1 (de) 2018-08-30 2021-07-07 HCW Biologics, Inc. Einzelkettige und mehrkettige chimäre polypeptide und verwendungen davon
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
CA3110498A1 (en) * 2018-08-31 2020-03-05 Yale University Enpp1 polypeptides and methods of using same
US20220002370A1 (en) 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
WO2020070678A2 (en) 2018-10-03 2020-04-09 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
TW202029980A (zh) 2018-10-26 2020-08-16 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
CA3118397A1 (en) 2018-11-01 2020-05-07 Shandong Newtime Pharmaceutical Co., Ltd. Bispecific antibody targeting cd3 and bcma, and uses thereof
BR112021008549A2 (pt) 2018-11-05 2022-01-04 Iovance Biotherapeutics Inc Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor
EP4257195A3 (de) 2018-11-09 2024-01-03 University of Massachusetts Anti-cfae-antikörper und verfahren zur verwendung
KR20210092769A (ko) 2018-11-16 2021-07-26 브리스톨-마이어스 스큅 컴퍼니 항-nkg2a 항체 및 그의 용도
CN112334483B (zh) 2018-11-27 2022-05-10 信达生物制药(苏州)有限公司 抗IL-23p19抗体及其用途
CN113348177A (zh) 2018-11-28 2021-09-03 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
EP3892632A4 (de) 2018-12-05 2022-08-17 Bica Therapeutics Inc. Modifiziertes produkt der fc-domäne von antikörpern
WO2020118011A1 (en) 2018-12-06 2020-06-11 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
WO2020115283A1 (en) 2018-12-07 2020-06-11 Baxalta GmbH Bispecific antibodies binding factor ixa and factor x
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
TW202039583A (zh) 2018-12-07 2020-11-01 瑞士商巴克斯歐塔有限公司 結合因子IXa及因子X的蛋白分子
WO2020128049A1 (en) 2018-12-21 2020-06-25 Kymab Limited Fixaxfx bispecific antibody with common light chain
US20220073613A1 (en) 2018-12-26 2022-03-10 Xilio Development, Inc. Activatable masked anti-ctla4 binding proteins
CN113227135A (zh) 2018-12-28 2021-08-06 斯帕克斯治疗公司 用于治疗癌症和其他疾病的对紧密连接蛋白18.2具有特异性的结合分子、其组合物和方法
AU2020204992A1 (en) 2019-01-04 2021-07-15 Resolve Therapeutics, Llc Treatment of sjogren's disease with nuclease fusion proteins
WO2020152290A1 (en) 2019-01-23 2020-07-30 Encefa Cd31 competitors and uses thereof
WO2020174370A2 (en) 2019-02-26 2020-09-03 Janssen Biotech, Inc. Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
CA3130303A1 (en) 2019-02-26 2020-09-03 Rgenix, Inc. High-affinity anti-mertk antibodies and uses thereof
MX2021010288A (es) 2019-03-01 2021-09-23 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes de tumores a partir de tumores liquidos y usos terapeuticos de los mismos.
CN113811332A (zh) 2019-03-05 2021-12-17 普罗塞纳生物科学有限公司 治疗al淀粉样变性的方法
CN113613676A (zh) 2019-03-19 2021-11-05 中外制药株式会社 包含对抗原的结合活性因mta而变化的抗原结合结构域的抗原结合分子及用于获得该抗原结合结构域的文库
JP7575401B2 (ja) 2019-04-03 2024-10-29 ジェンザイム・コーポレーション 断片化が低減した抗アルファベータｔｃｒ結合ポリペプチド
GB2589049C (en) 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
WO2020223565A1 (en) 2019-05-01 2020-11-05 Corvidia Therapeutics, Inc. Anti-il-6 antibody formulation
WO2020230091A1 (en) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
CN114206942A (zh) 2019-06-07 2022-03-18 美国安进公司 双特异性结合构建体
KR20220019018A (ko) 2019-06-07 2022-02-15 아르제넥스 비브이비에이 피하 투여에 적합한 FcRn 억제제의 약학적 제형
WO2020250033A1 (en) 2019-06-10 2020-12-17 Takeda Pharmaceutical Company Limited Combination therapies using cd-38 antibodies
EP3986918A1 (de) 2019-06-18 2022-04-27 Bayer Aktiengesellschaft Adrenomedullin-analoga zur langzeitstabilisierung und ihre verwendung
WO2020257639A1 (en) 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
US20230018417A1 (en) 2019-07-26 2023-01-19 Shire Human Genetic Therapies, Inc. Recombinant Heme Oxygenase-1 (HO-1) for the Treatment of Sickle Cell Disease
AU2020325753A1 (en) 2019-08-06 2022-03-03 Glaxosmithkline Intellectual Property Development Limited Biopharmacuetical compositions and related methods
WO2021030488A1 (en) 2019-08-12 2021-02-18 Bienvenue David Leonard 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
WO2021030633A1 (en) 2019-08-13 2021-02-18 Elpis Biopharmaceuticals Engineered interleukin-2 receptor beta agonists
CA3152027A1 (en) 2019-08-30 2021-03-04 Agenus Inc. Anti-cd96 antibodies and methods of use thereof
CN115279896A (zh) 2019-09-30 2022-11-01 比奥维拉迪维治疗股份有限公司 慢病毒载体配制品
JP2023503258A (ja) 2019-11-14 2023-01-27 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能サイトカインポリペプチド及びその使用方法
EP4058476A1 (de) 2019-11-15 2022-09-21 Enthera S.r.l. Tmem219-antikörper und ihre therapeutischen verwendungen
US20230039165A1 (en) 2019-11-21 2023-02-09 Enthera S.R.L. Igfbp3 antibodies and therapeutic uses thereof
MX2022006495A (es) 2019-11-29 2022-09-07 Kymab Ltd Tratamiento para la sobrecarga fisiologica de hierro.
US11739142B2 (en) 2019-12-18 2023-08-29 Hoffmann-La Roche Inc. Bispecific anti-CCL2 antibodies
KR20220148804A (ko) 2020-01-08 2022-11-07 아르젠엑스 비브이 천포창 장애의 치료 방법
US20230087600A1 (en) 2020-02-06 2023-03-23 Bristol-Myers Squibb Company Il-10 and uses thereof
CN116670163A (zh) 2020-02-11 2023-08-29 Hcw生物科技公司 治疗年龄相关疾病和炎性疾病的方法
AU2021219720A1 (en) 2020-02-11 2022-08-04 Immunitybio, Inc. Chromatography resin and uses thereof
EP3868396A1 (de) 2020-02-20 2021-08-25 Enthera S.R.L. Inhibitoren und verwendungen davon
JP2023516952A (ja) 2020-02-28 2023-04-21 ジェンザイム・コーポレーション 最適化された薬物コンジュゲーションのための改変された結合ポリペプチド
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
US20230174626A1 (en) 2020-03-27 2023-06-08 Glaxosmithkline Biologicals Sa Antibodies
WO2021202463A1 (en) 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies
KR20230004686A (ko) 2020-04-20 2023-01-06 젠자임 코포레이션 인간화 항-보체 인자 Bb 항체 및 그의 용도
AU2021259628A1 (en) 2020-04-24 2023-01-05 Millennium Pharmaceuticals, Inc. Anti-CD19 antibodies and uses thereof
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
KR20230010749A (ko) 2020-05-17 2023-01-19 아스트라제네카 유케이 리미티드 Sars-cov-2 항체 및 이를 선택 및 이용하는 방법
US20210363512A1 (en) 2020-05-22 2021-11-25 Formycon Ag ACE2 fusion proteins and uses thereof
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
CA3184351A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Bispecific binding constructs
WO2021251438A1 (ja) 2020-06-10 2021-12-16 株式会社バイカ・セラピュティクス エリスロポエチンポリペプチドを含む融合タンパク質
MX2022016340A (es) 2020-06-17 2023-01-24 Medimmune Ltd Fusiones heterodimericas de relaxina y usos de las mismas.
US20240228648A1 (en) 2020-06-23 2024-07-11 Jiangsu Kanion Pharmaceutical Co., Ltd. Anti-cd38 antibody and use thereof
WO2021262632A2 (en) * 2020-06-23 2021-12-30 Maddon Advisors Llc Anti-ccr5 monoclonal antibody-based compositions and methods
WO2021262963A1 (en) 2020-06-24 2021-12-30 Bioverativ Therapeutics Inc. Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
US20230355722A1 (en) 2020-06-29 2023-11-09 Resolve Therapeutics, Llc Treatment of sjogren’s syndrome with nuclease fusion proteins
EP4175650A1 (de) 2020-07-06 2023-05-10 Kiromic BioPharma, Inc. Mesothelinisoformbindende moleküle und chimäre pd1-rezeptormoleküle, zellen damit und verwendungen davon
AR122933A1 (es) 2020-07-10 2022-10-19 Novo Nordisk As Métodos para tratar la enfermedad cardiovascular
JP2023536904A (ja) 2020-08-06 2023-08-30 バイオベラティブ・ユーエスエイ・インコーポレイテッド 補体が媒介する疾患を有する対象における炎症性サイトカインおよび疲労
CN116234577A (zh) 2020-08-10 2023-06-06 阿斯利康(英国)有限公司 用于治疗和预防covid-19的sars-cov-2抗体
EP4454659A3 (de) 2020-08-18 2025-01-22 Cephalon LLC Anti-par-2-antikörper und verfahren zur verwendung davon
BR112023003366A2 (pt) 2020-08-25 2023-05-09 Gilead Sciences Inc Moléculas multiespecíficas de ligação ao antígeno que têm como alvo hiv e métodos de uso
KR20230060514A (ko) 2020-09-01 2023-05-04 다케다 야쿠힌 고교 가부시키가이샤 인터루킨-2 뮤테인 및 이의 용도
AR123480A1 (es) 2020-09-11 2022-12-07 Medimmune Ltd Moléculas de unión terapéuticas
DE102020125465A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202229312A (zh) 2020-09-29 2022-08-01 德商英麥提克生物技術股份有限公司 由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
US20220235137A1 (en) 2020-10-14 2022-07-28 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2022090469A2 (en) 2020-10-29 2022-05-05 Formycon Ag Ace2 fusion proteins and uses thereof
CA3202233A1 (en) 2020-11-18 2022-05-27 Kiromic BioPharma, Inc. Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
CA3200314A1 (en) 2020-12-01 2022-06-09 Peter Pavlik Tumor-associated antigens and cd-3 binding proteins, related compositions, and methods
IL303205A (en) 2020-12-03 2023-07-01 Amgen Inc Immunoglobuline constructs with multiple binding domains
CA3201560A1 (en) * 2020-12-08 2022-06-16 David Campbell Half-life extending compositions and methods
EP4259193A4 (de) 2020-12-09 2025-01-15 Janux Therapeutics Inc Zusammensetzungen und verfahren im zusammenhang mit tumoraktivierten antikörpern gegen psma und effektorzellantigene
US20240131064A1 (en) 2020-12-11 2024-04-25 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
WO2022133140A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
JP2023554456A (ja) 2020-12-18 2023-12-27 チューハイ トリノマブ ファーマシューティカル カンパニー リミテッド 呼吸器合胞体ウイルスに特異的に結合する分子
WO2022147196A2 (en) 2020-12-31 2022-07-07 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽
CA3205670A1 (en) 2021-01-22 2022-07-28 Kehao Zhao Anti-pd-l1 monoclonal antibodies and fusion proteins with interleukin-15 (il-15), interleukin-15 receptor 15 alpha or interleukin-2
EP4284919A1 (de) 2021-01-29 2023-12-06 Iovance Biotherapeutics, Inc. Verfahren zur herstellung von modifizierten tumorinfiltrierenden lymphozyten und deren verwendung in der adoptiven zelltherapie
TW202317612A (zh) 2021-03-01 2023-05-01 美商艾希利歐發展股份有限公司 用於治療癌症的ｃｔｌａ４及ｐｄ１／ｐｄｌ１抗體之組合
AU2022230384A1 (en) 2021-03-01 2023-09-07 Xilio Development, Inc. Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
MX2023009921A (es) 2021-03-03 2023-09-05 Formycon Ag Formulaciones de proteinas de fusion ace2-fc.
JP2024509184A (ja) 2021-03-05 2024-02-29 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍保存及び細胞培養組成物
EP4308691A1 (de) 2021-03-19 2024-01-24 Iovance Biotherapeutics, Inc. Verfahren zur expansion von tumorinfiltrierenden lymphozyten (til) im zusammenhang mit der cd39/cd69-auswahl und gen-knockout in tils
JP2024511414A (ja) 2021-03-23 2024-03-13 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球のｃｉｓｈ遺伝子編集及び免疫療法におけるその使用
CA3213163A1 (en) 2021-03-25 2022-09-29 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
CN117241828A (zh) 2021-03-31 2023-12-15 美国比奥维拉迪维股份有限公司 减少冷凝集素病患者的手术相关溶血
WO2022207785A1 (en) 2021-03-31 2022-10-06 Kymab Limited Antibodies to gfral
KR20230165285A (ko) 2021-03-31 2023-12-05 캠브리지 엔터프라이즈 리미티드 Gdf15 신호전달의 치료적 억제제
CN117425673A (zh) 2021-04-09 2024-01-19 武田药品工业株式会社 靶向补体因子d的抗体和其用途
IL307800A (en) 2021-04-19 2023-12-01 Iovance Biotherapeutics Inc Chimeric costimulatory receptors, chemokine receptors and their use in cellular immunotherapy
MX2023011712A (es) 2021-04-26 2023-10-12 Millennium Pharm Inc Anticuerpos anti receptor de adhesion acoplado a proteinas g e2 (adgre2) y usos de los mismos.
KR20240004286A (ko) 2021-04-26 2024-01-11 밀레니엄 파머슈티컬스 인코퍼레이티드 항 Clec12A 항체 및 이의 용도
JP2024519029A (ja) 2021-05-17 2024-05-08 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
WO2022248870A1 (en) 2021-05-28 2022-12-01 Glaxosmithkline Intellectual Property Development Limited Combination therapies for treating cancer
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
WO2022263357A1 (en) 2021-06-14 2022-12-22 Argenx Iip Bv Anti-il-9 antibodies and methods of use thereof
AU2022295067A1 (en) 2021-06-18 2023-12-21 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
US20240368262A1 (en) 2021-06-23 2024-11-07 Scholar Rock, Inc. A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
JP2024526898A (ja) 2021-07-22 2024-07-19 アイオバンス バイオセラピューティクス，インコーポレイテッド 固形腫瘍断片の凍結保存のための方法
JP2024527961A (ja) 2021-07-28 2024-07-26 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｋｒａｓ阻害剤と併用した腫瘍浸潤リンパ球療法によるがん患者の治療
JP2024530643A (ja) 2021-08-03 2024-08-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド バイオ医薬組成物および安定同位体標識ペプチドマッピング法
JP2024534041A (ja) * 2021-08-16 2024-09-18 イェール ユニバーシティー インターロイキン－１２バリアント及び使用方法
CA3227716A1 (en) 2021-08-20 2023-02-23 Intervet International B.V. Antibodies and igg fusion proteins with an extended half-life
AU2022332285A1 (en) 2021-08-23 2024-02-15 Immunitas Therapeutics, Inc. Anti-cd161 antibodies and uses thereof
IL311043A (en) 2021-08-30 2024-04-01 Lassen Therapeutics 1 Inc Anti-il-11rα antibodies
TW202323289A (zh) 2021-08-31 2023-06-16 日商大正製藥股份有限公司 抗生長激素抗體
EP4398915A1 (de) 2021-09-09 2024-07-17 Iovance Biotherapeutics, Inc. Verfahren zur erzeugung von til-produkten mittels pd-1-talen-knockdown
EP4404969A1 (de) 2021-09-24 2024-07-31 Iovance Biotherapeutics, Inc. Expansionsverfahren und mittel für tumorinfiltrierende lymphozyten
WO2023056362A1 (en) 2021-09-30 2023-04-06 Seagen Inc. B7-h4 antibody-drug conjugates for the treatment of cancer
JP2024537863A (ja) 2021-10-05 2024-10-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド がんを処置するための組合せ療法
EP4419561A2 (de) 2021-10-20 2024-08-28 Takeda Pharmaceutical Company Limited Zusammensetzungen zum targeting von bcma und verfahren zur verwendung davon
WO2023077015A2 (en) 2021-10-27 2023-05-04 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
TW202342095A (zh) 2021-11-05 2023-11-01 英商阿斯特捷利康英國股份有限公司 用於治療和預防ｃｏｖｉｄ—１９之組成物
EP4430167A1 (de) 2021-11-10 2024-09-18 Iovance Biotherapeutics, Inc. Verfahren zur expansionsbehandlung mit cd8-tumorinfiltrierenden lymphozyten
JP2024540480A (ja) 2021-11-17 2024-10-31 ディスク・メディシン・インコーポレイテッド 腎臓疾患の貧血を処置する方法
EP4437112A1 (de) 2021-11-24 2024-10-02 Formycon AG Verbesserte ace2-fusionsproteine
WO2023094571A1 (en) 2021-11-25 2023-06-01 Formycon Ag Stabilization of ace2 fusion proteins
IL313386A (en) 2021-12-15 2024-08-01 Medimmune Ltd TREATMENT USING HETERODIMERIC RELAXIN FUSIONS
CA3241017A1 (en) 2021-12-17 2023-06-22 Robert Ferris Combination therapies for hiv infections and uses thereof
MX2024006275A (es) 2022-01-18 2024-06-11 argenx BV Anticuerpos para galectina-10.
WO2023147486A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
EP4469065A1 (de) 2022-01-28 2024-12-04 Iovance Biotherapeutics, Inc. Zusammensetzungen und verfahren für cytokinassoziierte tumorinfiltrierende lymphozyten
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
EP4486459A1 (de) 2022-03-03 2025-01-08 Yale University Humanisierte 3e10-antikörper, varianten und antigenbindende fragmente davon
KR20240159839A (ko) 2022-03-09 2024-11-06 아스트라제네카 아베 FRα에 대한 결합 분자
AU2023229967A1 (en) 2022-03-11 2024-08-08 Astrazeneca Ab A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
WO2023196877A1 (en) 2022-04-06 2023-10-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
AU2023262192A1 (en) 2022-04-29 2024-12-05 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
US12060426B2 (en) 2022-04-29 2024-08-13 23Andme, Inc. Anti-ULBP6 antibodies
US11780910B1 (en) 2022-05-02 2023-10-10 Novo Nordisk A/S Anti-ANGPTL3 antibodies suitable for high concentration compositions and subcutaneous administration
WO2023220608A1 (en) 2022-05-10 2023-11-16 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
AU2023269782A1 (en) 2022-05-10 2025-01-02 Elpis Biopharmaceuticals Engineered interleukin-2 receptor beta reduced-binding agonist
AU2023291786A1 (en) 2022-06-15 2024-12-12 argenx BV Ph-dependent hsa-binding molecules and methods of use
AU2023293090A1 (en) 2022-06-15 2025-01-30 Bioverativ Usa Inc. Anti-complement c1s antibody formulation
WO2023250507A1 (en) 2022-06-24 2023-12-28 Bioverativ Usa Inc. Methods for treating complement-mediated diseases
WO2024011114A1 (en) 2022-07-06 2024-01-11 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
AU2023307948A1 (en) 2022-07-12 2025-01-09 Cytomx Therapeutics, Inc. Epcam immunoconjugates and uses thereof
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
WO2024026395A1 (en) 2022-07-27 2024-02-01 Cephalon Llc Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease
AR130041A1 (es) 2022-07-27 2024-10-30 Cephalon Llc Formulaciones de anticuerpos anti-tl1a
US20240052051A1 (en) 2022-07-29 2024-02-15 Regeneron Pharmaceuticals, Inc. Anti-tfr:payload fusions and methods of use thereof
WO2024026494A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to transferrin receptor 1
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024038193A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
TW202413410A (zh) 2022-08-18 2024-04-01 英商英美偌科有限公司 多域結合分子
WO2024042112A1 (en) 2022-08-25 2024-02-29 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins and uses thereof
WO2024050421A2 (en) 2022-08-30 2024-03-07 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting programmed cell death protein 1 (pd-1)
AR130550A1 (es) 2022-09-21 2024-12-18 Sanofi Biotechnology Anticuerpo anti-il-1r3 humanizado y métodos de uso
TW202432574A (zh) 2022-10-25 2024-08-16 比利時商艾伯霖克斯公司 具有增強的效應子功能之糖基工程化Ｆｃ變體多肽
WO2024098027A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
US20240182561A1 (en) 2022-11-04 2024-06-06 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2024102674A1 (en) 2022-11-13 2024-05-16 Generate Biomedicines, Inc. Antigen binding molecules targeting sars-cov-2
US20240173426A1 (en) 2022-11-14 2024-05-30 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
US20240158515A1 (en) 2022-11-14 2024-05-16 Regeneron Pharmaceuticals, Inc. Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof
WO2024107752A2 (en) 2022-11-15 2024-05-23 Onestone Therapeutics Llc Compositions and methods for immunomodulatory bifunctional fusion molecules
WO2024105244A1 (en) 2022-11-18 2024-05-23 Universiteit Antwerpen Igfbp2 as biomarker for thoracic aortic aneurysm and dissections
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
US12110344B2 (en) 2022-11-21 2024-10-08 Dianthus Therapeutics Opco, Inc. Antibodies that bind to cis and uses thereof
WO2024112711A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Methods for assessing proliferation potency of gene-edited t cells
TW202438534A (zh) 2022-12-09 2024-10-01 瑞典商阿斯特捷利康公司 使用異二聚物鬆弛素融合體的給藥方案
EP4386084A1 (de) 2022-12-14 2024-06-19 Formycon AG Verbesserte ace2-fusionsproteine
WO2024133161A1 (en) 2022-12-19 2024-06-27 Astrazeneca Ab Treatment of autoimmune disease
TW202434642A (zh) 2023-01-06 2024-09-01 美商拉森醫療公司 用於治療甲狀腺眼病之抗ＩＬ—１１Ｒα抗體
TW202430560A (zh) 2023-01-06 2024-08-01 美商拉森醫療公司 抗ｉｌ－１８ｂｐ抗體
WO2024147934A1 (en) 2023-01-06 2024-07-11 Takeda Pharmaceutical Company Limited Anti-cd38 antibodies for the treatment of autoimmune diseases
WO2024151515A2 (en) 2023-01-09 2024-07-18 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
WO2024150074A2 (en) 2023-01-13 2024-07-18 Takeda Pharmaceutical Company Limited Coronavirus antibodies and therapeutic uses thereof
WO2024156720A1 (en) 2023-01-25 2024-08-02 Medimmune Limited Migraine therapy
WO2024170660A1 (en) 2023-02-16 2024-08-22 Astrazeneca Ab Combination therapies for treatment of cancer with therapeutic binding molecules
WO2024182714A1 (en) 2023-03-02 2024-09-06 Alloy Therapeutics, Inc. Anti-cd22 antibodies and uses thereof
WO2024184206A1 (en) 2023-03-03 2024-09-12 Astrazeneca Ab Pharmaceutical formulation comprising heterodimeric relaxin fusion proteins and uses thereof
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
EP4428158A1 (de) 2023-03-10 2024-09-11 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Gegen lungenkrebs gerichtete humane antikörper und therapeutische verwendungen davon
EP4428159A1 (de) 2023-03-10 2024-09-11 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Melanom-abzielende menschliche antikörper und ihre therapeutische verwendung
WO2024192065A1 (en) 2023-03-14 2024-09-19 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
GB202306345D0 (en) 2023-04-28 2023-06-14 Immunocore Ltd Binding molecules
WO2024238790A1 (en) 2023-05-17 2024-11-21 Odyssey Therapeutics, Inc. Modified single-domain antibodies
GB202309512D0 (en) 2023-06-23 2023-08-09 Astrazeneca Ab Lilrb2 binding proteins and uses thereof
WO2025006846A2 (en) 2023-06-29 2025-01-02 Odyssey Therapeutics, Inc. Anti-trailr2 antigen-binding proteins and uses thereof
WO2025014774A1 (en) 2023-07-07 2025-01-16 Viridian Therapeutics, Inc. Methods of treating active and chronic thyroid eye disease
WO2025015318A2 (en) 2023-07-13 2025-01-16 Iovance Biotherapeutics, Inc. Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
WO2025019790A1 (en) 2023-07-19 2025-01-23 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
EP0368684B2 (de) 1988-11-11 2004-09-29 Medical Research Council Klonierung von Immunglobulin sequenzen aus den variabelen Domänen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0394827A1 (de) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimärische CD4-Immunoglobulin-Polypeptide
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
CA2071867A1 (en) 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
CA2078689C (en) 1990-03-20 2003-02-11 Sherie L. Morrison Chimeric antibodies with receptor binding ligands in place of their constant region
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JPH07500961A (ja) 1990-10-01 1995-02-02 ユニバーシティ オブ コネチカット 細胞による選択的内在化を目的としたウイルス及び細胞の標的設定
JP3583420B2 (ja) 1990-10-05 2004-11-04 メダレツクス・インコーポレーテツド 二特異的試薬を用いた標的免疫化
WO1992008802A1 (en) 1990-10-29 1992-05-29 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DK0517895T3 (da) 1990-12-14 1997-04-07 Univ California Kimæriske kæder til receptorforbundne signaltransduktionsveje
ATE193724T1 (de) * 1991-03-12 2000-06-15 Biogen Inc Cd2 bindender bereich für das lymphocyten- funktion assoziierte antigen-3
DE69233367T2 (de) 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla Bibliotheken heterodimerer rezeptoren mittels phagemiden
ATE144624T1 (de) 1991-04-26 1996-11-15 Surface Active Ltd Neue antikörper und verfahren zu ihrer verwendung
AU666852B2 (en) 1991-05-01 1996-02-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
JPH06510524A (ja) 1991-05-14 1994-11-24 ユニバーシティ オブ コネチカット 免疫原性タンパク質をコードする遺伝子の標的への配達
EP0519596B1 (de) 1991-05-17 2005-02-23 Merck & Co. Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
AU2160992A (en) 1991-06-05 1993-01-12 Board Of Regents Acting For And On Behalf Of The University Of Michigan, The Targeted delivery of genes encoding secretory proteins
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US20020102257A1 (en) 1998-09-21 2002-08-01 Leslie Sid Johnson Human-murine chimeric antibodies against respiratory syncytial virus
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
WO1993014188A1 (en) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
DE69332948T2 (de) 1992-03-05 2003-11-27 Board Of Regents, The University Of Texas System Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
JPH07505773A (ja) 1992-04-03 1995-06-29 ヤング　アレキサンダー　ティー 標的化されたウイルスベクターを用いた遺伝子治療
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
EP0598877B1 (de) 1992-06-09 1999-07-28 Hoppe Ag Riegel und türschloss
JPH08501085A (ja) 1992-08-26 1996-02-06 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗腫瘍剤としてのサイトカインｉｐ−１０の利用
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2146747C (en) 1992-10-09 2006-12-19 Brian A. Naughton Liver reserve cells
EP0911413A3 (de) 1992-12-03 2000-11-15 Genzyme Corporation Mindestadenovirus-Vector zur Gentherapie
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
ATE267877T1 (de) 1993-01-07 2004-06-15 Sequenom Inc Dns - sequenzierung durch massenspektronomie
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
ATE300610T1 (de) 1994-01-31 2005-08-15 Univ Boston Bibliotheken aus polyklonalen antikörpern
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
CZ25697A3 (en) 1994-07-29 1997-09-17 Smithkline Beecham Plc Novel compounds
DE69630514D1 (de) 1995-01-05 2003-12-04 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
EP1323346B1 (de) 1995-01-17 2006-06-28 The Brigham And Women's Hospital, Inc. Rezeptorspezifischer Transepithelealer Transport von Immunogenen
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
EP1709970A1 (de) 1995-04-27 2006-10-11 Abgenix, Inc. Menschliche Antikörper gegen EGFR, von immunisierten transgenen Mäusen produziert
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
JP2000507912A (ja) 1995-08-31 2000-06-27 アルカームズ コントロールド セラピューティックス，インコーポレイテッド 作用剤の徐放性組成物
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
AU2063197A (en) 1996-03-04 1997-09-22 Massachusetts Institute Of Technology Materials and methods for enhancing cellular internalization
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
ATE279947T1 (de) * 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
CA2248868A1 (en) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
EP1972194A1 (de) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgene Säugetiere mit menschlichen IG-Orten mit mehreren VH- und VK-Regionen und darin erzeugten Antikörpern
PT954282E (pt) 1997-01-16 2005-06-30 Massachusetts Inst Technology Preparacao de particulas para inalacao
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
RU2224766C2 (ru) 1997-04-14 2004-02-27 Микромет Аг Способ получения рецепторов для человеческих антигенов и их применение
DE69830901T2 (de) * 1997-05-02 2006-05-24 Genentech Inc., San Francisco ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6133166A (en) 1997-07-01 2000-10-17 The Procter & Gamble Company Cleaning articles comprising a cellulosic fibrous structure having discrete basis weight regions treated with a high internal phase inverse emulsion
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
CA2309541C (en) 1997-11-03 2011-01-11 Human Genome Sciences, Inc. Vegi, an inhibitor of angiogenesis and tumor growth
JP2002505086A (ja) 1998-02-25 2002-02-19 レキシジェン ファーマシューティカルズ コーポレイション 抗体ベースの融合タンパク質の循環半減期の増強
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69907456T2 (de) 1998-06-24 2004-03-25 Advanced Inhalation Research, Inc., Cambridge Grosse poröse partikel ausgestossen von einem inhalator
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
US6572856B1 (en) * 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2366713A3 (de) 1999-01-15 2012-06-27 Genentech, Inc. Polypeptidvarianten mit veränderter Effektorfunktion
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
US7229619B1 (en) * 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
ATE474854T1 (de) * 2000-01-27 2010-08-15 Medimmune Llc Rsv neutralisierende antikörper mit sehr hohen affinität
CA2399832C (en) 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
EP2341074A1 (de) * 2000-03-01 2011-07-06 MedImmune, LLC Anti-rsv-f-protein-antikörper
IL151348A0 (en) 2000-04-13 2003-04-10 Univ Rockefeller Enhancement of antibody-mediated immune responses
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
US7658921B2 (en) * 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
CA2444680A1 (en) 2001-04-18 2002-10-31 Dyax Corp. Binding molecules for fc-region polypeptides
US6911321B2 (en) 2001-12-19 2005-06-28 Genentech, Inc. Non-human primate Fc receptors and methods of use
US7219797B2 (en) * 2002-01-14 2007-05-22 Alliance Packaging Llc. Box with insert that extends from a side and that divides the box into compartments and methods for forming and using
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
EP1534335B9 (de) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
BRPI0314814C1 (pt) 2002-09-27 2021-07-27 Xencor Inc anticorpo compreendendo uma variante de fc
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DE60334141D1 (de) 2002-10-15 2010-10-21 Facet Biotech Corp VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en) * 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2545539A1 (en) * 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
AU2005302453A1 (en) 2004-10-29 2006-05-11 Medimmune, Llc Methods of preventing and treating RSV infections and related conditions
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
US8775090B2 (en) 2008-12-12 2014-07-08 Medimmune, Llc Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule

Also Published As

Publication number Publication date
EP2357187A1 (de) 2011-08-17
AU2002248184B2 (en) 2008-01-10
JP2008054679A (ja) 2008-03-13
US8475792B2 (en) 2013-07-02
US20140377181A1 (en) 2014-12-25
US20070122403A1 (en) 2007-05-31
WO2002060919A2 (en) 2002-08-08
US20130052135A1 (en) 2013-02-28
JP4336498B2 (ja) 2009-09-30
US7670600B2 (en) 2010-03-02
ES2727425T3 (es) 2019-10-16
WO2002060919A3 (en) 2003-09-04
US8323962B2 (en) 2012-12-04
EP2341060B1 (de) 2019-02-20
US9562100B2 (en) 2017-02-07
WO2002060919A9 (en) 2003-01-03
EP3569610A3 (de) 2020-03-18
JP2010154855A (ja) 2010-07-15
US7083784B2 (en) 2006-08-01
US20100189718A1 (en) 2010-07-29
EP1355919A2 (de) 2003-10-29
CY1111283T1 (el) 2015-08-05
JP5444010B2 (ja) 2014-03-19
JP2014050385A (ja) 2014-03-20
US8795661B2 (en) 2014-08-05
JP2016020344A (ja) 2016-02-04
US7704497B2 (en) 2010-04-27
EP2354149A1 (de) 2011-08-10
EP3569610A2 (de) 2019-11-20
EP1355919A4 (de) 2005-02-09
AU2002248184C1 (en) 2018-01-04
JP6125949B2 (ja) 2017-05-10
US20110311454A1 (en) 2011-12-22
JP2017079771A (ja) 2017-05-18
DK1355919T3 (da) 2011-03-14
US20060198840A1 (en) 2006-09-07
CA2431600A1 (en) 2002-08-08
JP2009261394A (ja) 2009-11-12
EP2341060A1 (de) 2011-07-06
US20030190311A1 (en) 2003-10-09
JP4336376B2 (ja) 2009-09-30
EP2354149B1 (de) 2017-08-30
DE60143544D1 (de) 2011-01-05
US20130272964A1 (en) 2013-10-17
US8012476B2 (en) 2011-09-06
PT1355919E (pt) 2011-03-02
JP5265446B2 (ja) 2013-08-14
CA2431600C (en) 2012-04-17
JP2005501514A (ja) 2005-01-20
EP1355919B1 (de) 2010-11-24
JP6268127B2 (ja) 2018-01-24
ES2649037T3 (es) 2018-01-09

Similar Documents

Publication Publication Date Title
ATE489395T1 (de) Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
ATE223229T1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
BR9507594B1 (pt) anticorpo monoclonal com scfv humanizado, molécula de ácido nucleico recombinante e proteìna recombinante.
CY1118037T1 (el) Αντισωματα εναντι του αβητα και h χρηση τους
EA200001041A1 (ru) Антитела к cd23, их производные и их терапевтическое применение
DK1135498T3 (da) Antistofvarianter med höjere bindingsaffinitet end forældreantistoffer
BR9908226A (pt) Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
AT500379A3 (de) Tau-proteine
CY1108545T1 (el) Πρωτεϊνες υπομοναδας υποδοχεα κυτοκινης θηλαστικου, σχετικα αντιδραστηρια και μεθοδοι
DE60333306D1 (de) Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen
CY1110877T1 (el) Αλλαγη των συγγενειων συνδεσης me fcrn ή των ημιζωων ορου αντισωματων με μεταλλαξιγενεση
DE60032486D1 (de) Prion protein peptide und deren verwendung
CY1117756T1 (el) Χιμαιρικα υβριδια μονομερους-διμερους ανοσοσφαιρινης
BR0212256A (pt) Proteìnas de fusão de transferrina modificadas
ATE248605T1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
WO2003060080A3 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
CY1112447T1 (el) Ανθρωπινα αντισωματα για την ιντερλευκινη (ιντεrleukin) 15 (il-15)
CY1110759T1 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
ATE255906T1 (de) Antikörper gegen cd40
WO2006083964A3 (en) Modified fusion molecules for treatment of allergic disease
ES2098274T3 (es) Anticuerpos monoclonales.
DE69233125D1 (de) Inhibitorische immunglobulin-polypeptide gegen den pdgf beta-rezeptor
ATE260977T1 (de) Immunoglobulin-bindende proteine
DK1572745T3 (da) Antistof anti-humant NogoA og dets farmaceutiske anvendelse
ATE452650T1 (de) Transferrin-fusionsproteinbibliotheken

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1355919

Country of ref document: EP